Meeting
2023 ASCO Genitourinary Cancers Symposium
The impact of homologous recombination repair (HRR) gene mutation status on treatment (tx) patterns and clinical outcomes among patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US).
Presenter
Pedro C. Barata, MD, MSc
Tulane University
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 97)
DOI
10.1200/JCO.2023.41.6_suppl.97
Abstract #
97
Poster Bd #
D13
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
Homologous recombination repair gene mutation (HRRm) testing patterns and treatment selection from a real-world cohort of patients with metastatic castration-resistant prostate cancer (mCRPC).
Speaker: Neal D. Shore, MD, FACS
Videos & Slides
2024 ASCO Annual Meeting
Matching-adjusted indirect comparisons (MAICs) of talazoparib plus enzalutamide (TALA+ENZA) versus olaparib plus abiraterone and prednisone/prednisolone (OLAP+AAP) for first-line (1L) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair mutations (HRRm)/BRCAm.
Speaker: Allison Thompson, PharmD
Speaker: Deepa Rangachari, MD
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
Efficacy of olaparib (O) plus abiraterone (A) versus placebo (P) plus A in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with single homologous recombination repair gene mutations (HRRm) in the PROpel trial.
Speaker: Neal D. Shore, MD, FACS